PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Non-alcoholic fatty liver disease (NAFLD) has become a prevalent chronic liver disease, however, drugs to treat this disease are still lacking. Here, the authors show that PPDPF inhibits the development of hepatic steatosis by negatively regulating mTORC1-S6K-SREBP1 signaling, which provides a poten...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ning Ma, Yi-Kang Wang, Sheng Xu, Qian-Zhi Ni, Qian-Wen Zheng, Bing Zhu, Hui-Jun Cao, Hao Jiang, Feng-Kun Zhang, Yan-Mei Yuan, Er-Bin Zhang, Tian-Wei Chen, Ji Xia, Xu-Fen Ding, Zhen-Hua Chen, Xiu-Ping Zhang, Kang Wang, Shu-Qun Cheng, Lin Qiu, Zhi-Gang Li, Yong-Chun Yu, Xiao-Fan Wang, Bin Zhou, Jing-Jing Li, Dong Xie
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/8537535d3b06469c9a7a4a00e3cfe23a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Non-alcoholic fatty liver disease (NAFLD) has become a prevalent chronic liver disease, however, drugs to treat this disease are still lacking. Here, the authors show that PPDPF inhibits the development of hepatic steatosis by negatively regulating mTORC1-S6K-SREBP1 signaling, which provides a potential therapeutic candidate for NAFLD treatment.

Ejemplares similares